SeaStar_SM_LogoCard.png
SeaStar Medical Reports 2023 Financial Results and Provides a Business Update
17 avr. 2024 16h00 HE | SeaStar Medical Holding Corporation
DENVER, April 17, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary...
SeaStar_SM_LogoCard.png
SeaStar Medical to Present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference
11 avr. 2024 08h30 HE | SeaStar Medical Holding Corporation
DENVER, April 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
SeaStar_SM_LogoCard.png
SeaStar Medical to Restate Financials, Sets Business Update Call for April 17
27 mars 2024 08h30 HE | SeaStar Medical Holding Corporation
Restatement of non-cash items is not expected to materially impact cash position or operations DENVER, March 27, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a...
SeaStar_SM_LogoCard.png
SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients
12 mars 2024 08h30 HE | SeaStar Medical Holding Corporation
Company plans to hold a business update conference call in April DENVER, March 12, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial stage medical device...
SeaStar_SM_LogoCard.png
SeaStar Medical-Sponsored Symposium Featuring Experts Discussing Pediatric Acute Kidney Injury and the Selective Cytopheretic Device to be Webcast Live at AKI & CRRT 2024
11 mars 2024 16h05 HE | SeaStar Medical Holding Corporation
March 13 webcast showcasing Quelimmune™ scientific background and clinical data for pediatric AKI due to sepsis or a septic condition will be available on seastarmedical.com DENVER, March 11, 2024...
SeaStar_SM_LogoCard.png
Manuscript Discussing the Benefit of SeaStar Medical’s Selective Cytopheretic Device in Patients with Heart Failure and Hyperinflammation Published in European Journal of Heart Failure
27 févr. 2024 08h30 HE | SeaStar Medical Holding Corporation
Interest continues to grow in developing new strategies to reduce systemic inflammation as a means of improving outcomes in heart failure patients DENVER, Feb. 27, 2024 (GLOBE NEWSWIRE)...
SeaStar_SM_LogoCard.png
FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical’s Selective Cytopheretic Device for Pediatric Acute Kidney Injury
22 févr. 2024 07h53 HE | SeaStar Medical Holding Corporation
SCD-PED (Pediatric) is the first FDA-approved product in the Company’s Quelimmune™ product family DENVER, Feb. 22, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a...
SeaStar_SM_LogoCard.png
SeaStar Medical Granted Canadian Patent with Broad Claims Covering the Selective Cytopheretic Device Technology
01 févr. 2024 08h30 HE | SeaStar Medical Holding Corporation
DENVER, Feb. 01, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...
SeaStar_SM_LogoCard.png
SeaStar Medical Announces Pricing of $9.0 Million Registered Direct Offering Priced At-the-Market
26 janv. 2024 08h05 HE | SeaStar Medical Holding Corporation
DENVER, Jan. 26, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (the “Company”), a medical technology company developing proprietary solutions to reduce the consequences...
SeaStar_SM_LogoCard.png
SeaStar Medical Appoints David A. Green as Chief Financial Officer
11 janv. 2024 16h05 HE | SeaStar Medical Holding Corporation
DENVER, Jan. 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...